🔔 Earnings Alert
Piramal Pharma reports Q3 net profit down 63.6% YoY to ₹3.68 crore, despite revenue growth of 12.5% to ₹2,204.2 crore.
Piramal Pharma Analyst Rating
based on 7 analysts
100.00%
Buy
0.00%
Hold
0.00%
Sell
Based on 7 analysts offering long term price targets for Piramal Pharma. An average target of ₹306.29
Source: S&P Global Market Intelligence
Piramal Pharma Share analysis
Piramal Pharma price forecast by 7 analysts
Upside of40.15%
High
₹340
Target
₹306.29
Low
₹270
Piramal Pharma target price ₹306.29, a slight upside of 40.15% compared to current price of ₹239.3. According to 7 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Piramal Pharma revenue growth forecast
Expected growth rate Q1, FY2027:47.78%
Forecast
Actual
Including amortisation and stock based compensations
Piramal Pharma EPS growth forecast
EPS estimate Q1, FY2027:5038.46%
Forecast
Actual
Source: S&P Global Market Intelligence
Piramal Pharma Performance
Day's Low
Day's High
₹205.25Day's Price Range₹24552 Week's Low
52 Week's High
₹114.3552-Week Price Range₹307.9
| Returns % | |
| 1 Month Return | -17.62 % |
| 3 Month Return | -12.95 % |
| 1 Year Return | + 53.8 % |
| Market Stats | |
| Previous Close | ₹218.55 |
| Open | ₹205.25 |
| Volume | 1.45Cr |
| Upper Circuit | - |
| Lower Circuit | - |
| Market Cap | ₹28,974.23Cr |
Piramal Pharma Key Statistics
| P/E Ratio | 728.5 |
| PEG Ratio | 1255.17 |
| Market Cap | ₹28,974.23 Cr |
| P/B Ratio | 2.54 |
| EPS | 0.13 |
| Dividend Yield | 0.09 |
| Sector | Pharmaceuticals |
| ROE | 6.53 |
Piramal Pharma Peer Comparison
Company | Analyst View | Market Cap | 5 Year CAGR | Debt to Asset Ratio | Net Profit | Yearly Revenue |
|---|---|---|---|---|---|---|
| BUY | ₹28,974.23 Cr | 3.01% | 0.58 | ₹17 Cr | ₹8,171 Cr | |
| BUY | ₹24,827.72 Cr | 95.74% | 0.52 | ₹300 Cr | ₹1,051 Cr | |
| BUY | ₹14,049.46 Cr | 13.69% | 0.57 | ₹72 Cr | ₹6,702 Cr | |
| NA | ₹5,258.87 Cr | -3.9% | 0.79 | -₹388 Cr | ₹75 Cr | |
| BUY | ₹13,961.83 Cr | 41.08% | 0.68 | ₹218 Cr | ₹1,296 Cr |
Piramal Pharma Mutual Fund Holdings
About Piramal Pharma
Share Price: ₹239.30 per share as on 29 Jan, 2025 04:01 PM
Market Capitalisation: ₹28,974.23Cr as of today
Revenue: ₹2,204.22Cr as on December 2024 (Q4 24)
Net Profit: ₹3.68Cr as on December 2024 (Q4 24)
Listing date: 19 Oct, 2022
Chairperson Name: Nandini Piramal
| Organisation | Piramal Pharma |
| Headquarters | |
| Industry | Pharmaceuticals |
| E-voting on shares | Click here to vote |
What's happening today
Today's Timeline - Invalid Date
06:47 AM
-Piramal Pharma reports Q3 net profit drops 63% YoY to ₹3.7 crore, despite revenue growth of 12.5% to ₹2,204 crore.
10:16 AM
-Piramal Pharma shares drop 2% following Q3 results, with net profit decline raising concerns over profitability.
11:22 AM
-Standalone net sales for December 2024 rise 21.89% YoY to ₹1,248.32 crore, with net profit up 59.81%.
Today's Timeline - Invalid Date
11:33 AM
-Piramal Pharma's Q3 results show revenue growth but significant profit decline, raising concerns about operational efficiency.
11:53 AM
-Piramal Pharma's stock trades at ₹222.60 after Q3 results, with mixed analyst ratings indicating potential for recovery.
Key events for Piramal Pharma Ltd
Piramal Pharma Reports Mixed Q3 FY25 Results - 28 Jan, 2025
Piramal Pharma's Q3 FY25 results showed a 63.6% drop in PAT to Rs 3.6 crore, despite a 12.5% revenue increase to Rs 2,204.2 crore. The decline in PAT was attributed to sequential performance, while strong growth in CDMO, CHG, and ICH segments was noted. E-commerce sales surged over 40% year-on-year. The stock fell 2.25% to Rs 218.9 post-results announcement.Piramal Pharma Launches New Drug, Stock Volatile - 23 Jan, 2025
Piramal Pharma's division launched Chlorpromazine Hydrochloride for Injection in the US, leading to initial stock gains of 4%, but later losses were observed. The stock remains active in the market.Piramal Pharma Launches Chlorpromazine Injection in US - 22 Jan, 2025
Piramal Pharma's Critical Care division has launched Chlorpromazine Hydrochloride for Injection in the US, expanding its generic injectables portfolio. This follows several recent product launches, enhancing their critical care offerings.Piramal Pharma Stock Rallies Amid Market Weakness - 13 Jan, 2025
On January 13, 2025, Piramal Pharma shares surged over 8%, snapping a three-day losing streak. Analysts maintain a buy rating, citing strong potential in the CDMO sector and margin expansion. Despite recent declines, investor confidence remains buoyed by positive brokerage outlooks.Jefferies Upgrades Piramal Pharma Target Price - 10 Jan, 2025
Jefferies has maintained a BUY rating for Piramal Pharma Ltd, raising the target price to ₹310 from ₹260, highlighting it as a top pick in the CDMO space.Piramal Pharma Appoints New CEO for Healthcare Division - 07 Jan, 2025
Piramal Pharma has appointed Sai Ramana Ponugoti as CEO of India Consumer Healthcare, effective January 6, 2025. The stock rose 1.70% following the announcement, reflecting positive market sentiment. Ponugoti brings over 20 years of leadership experience from Procter & Gamble, enhancing the company's strategic direction.Piramal Pharma Receives Buy Call Amid Price Drop - 04 Jan, 2025
Piramal Pharma shares closed at Rs 255, down 1% from the previous day. ICICI Direct issued a Buy recommendation with a target price of Rs 320, suggesting a potential upside of 25%.
Insights on Piramal Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTMF Holding Up
Mutual Funds have increased holdings from 11.21% to 11.66% in Dec 2024 quarter
- POSITIVE IMPACT
Best in 1 Year
In the last 1 year, PPLPHARMA has outperformed top 5 stocks with highest market-cap in Pharmaceuticals
- POSITIVE IMPACT
Price Rise
In the last 6 months, PPLPHARMA stock has moved up by 53.0%
NO EFFECTPromoter Holding Unchanged
Promoters holdings remained unchanged at 34.95% of holdings in Dec 2024 quarter
NEGATIVE IMPACTFII Holding Down
Foreign Institutions have decreased holdings from 13.73% to 13.68% in Dec 2024 quarter
- NEGATIVE IMPACT
Retail Holding Down
Retail Investor have decreased holdings from 19.07% to 18.87% in Dec 2024 quarter
- NEGATIVE IMPACT
Revenue Fall
Revenue is down for the last 2 quarters, 2.32K Cr → 2.23K Cr (in ₹), with an average decrease of 3.7% per quarter
- NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, 22.59 Cr → 3.68 Cr (in ₹), with an average decrease of 83.7% per quarter
Piramal Pharma Financials
Index Inclusions
Piramal Pharma Shareholding Pattern
| Investors | Holdings % | FY Quarter | 3M change |
|---|---|---|---|
| Promoter Holdings | 34.95% | 0.00 | |
| Foreign Institutions | 13.68% | ||
| Mutual Funds | 11.66% | 4.00 | |
| Retail Investors | 18.87% | ||
| Others | 20.85% |
Piramal Pharma Key Indicators
Piramal Pharma Valuation
Piramal Pharma in the last 5 years
Lowest (-516.41x)
January 5, 2024
Industry (53.05x)
January 28, 2025
Today (728.50x)
January 28, 2025
Highest (2011.42x)
June 25, 2024
Piramal Pharma Earnings and Dividends
Piramal Pharma Ltd Earnings Results
Piramal Pharma Ltd’s net profit jumped 350% since last year same period to ₹22.59Cr in the Q2 2024-2025. On a quarterly growth basis, Piramal Pharma Ltd has generated 125.49% jump in its net profits since last 3-months.
Read More about Earnings ResultsPiramal Pharma Ltd Dividends May,2024
In the quarter ending March 2024, Piramal Pharma Ltd has declared dividend of ₹0.11 - translating a dividend yield of 0.05%.
Read More about Dividends
Piramal Pharma Technicals Summary
Bearish
Neutral
Bullish
Piramal Pharma Ltd is currently in a Bullish trading position according to technical analysis indicators.
FAQs on Piramal Pharma Ltd
What is Piramal Pharma Ltd price today?
Piramal Pharma Ltd share price today stands at ₹239.3, Open: ₹205.25, Previous Close: ₹218.55, High: ₹245, Low: ₹205.25, 52 Week High: ₹307.9, 52 Week Low: ₹114.35.
How to Buy Piramal Pharma Ltd Share in India?
- Get a PAN card
- Open a Demat account
- Open a Trading account
- Link your Demat account to your Trading account
- Fund your Trading account
- Place an order to buy Piramal Pharma Ltd shares
Is Piramal Pharma Ltd listed on NSE?
Piramal Pharma Ltd is listed on NSE
Is Piramal Pharma Ltd listed on BSE?
Piramal Pharma Ltd is listed on BSE
What are today's High and Low prices of Piramal Pharma Ltd?
- Today's highest price of Piramal Pharma Ltd is ₹245.
- Today's lowest price of Piramal Pharma Ltd is ₹205.25.
What are today's traded volumes of Piramal Pharma Ltd?
Today's traded volume of Piramal Pharma Ltd(PPLPHARMA) is 1.45Cr.
What is today's market capitalisation of Piramal Pharma Ltd?
Today's market capitalisation of Piramal Pharma Ltd(PPLPHARMA) is ₹28974.23Cr.
What is the 52 Week High and Low Range of Piramal Pharma Ltd?
How much percentage Piramal Pharma Ltd is down from its 52 Week High?
Piramal Pharma Ltd (PPLPHARMA) share price is ₹239.3. It is down -22.28% from its 52 Week High price of ₹307.9
How much percentage Piramal Pharma Ltd is up from its 52 Week low?
Piramal Pharma Ltd (PPLPHARMA) share price is ₹239.3. It is up 109.27% from its 52 Week Low price of ₹114.35
What are the historical returns of Piramal Pharma Ltd?
What is the PE ratio of Piramal Pharma Ltd today?
PE Ratio of Piramal Pharma Ltd is 728.5
PE ratio = Piramal Pharma Ltd Market price per share / Piramal Pharma Ltd Earnings per share